Menu
No results found.
Weekly Share Price & Valuation Overview
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management. In addition, the company develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056, SAL001, SAL023 medicine used for treating osteoporosis; and Fotagliptin and SAL015 for diabetes which are under phase III clinical trial. Further, it develops Sacubitril Allisartan Calcium and SAL007 medicine for chronic heart failure; SAL003 to treat hypercholesterolemia; and SAL0114 for depressant indications that is in phase I clinical trial. Additionally, the company's preclinical products are SAL023 for osteoporosis; SAL0112 to treat diabetes; and SAL008 for the treatment of tumors. Furthermore, it develops medical devices, such as intracranial segment of vertebral artery stent, which is under clinical trials for Neurology intervention; SaExtenVena cava filter and Microneedle perfusion absolute ethanol delivery system used for Peripheral vascular intervention; and LAMax LAAC Left Atrial Appendage Occluder used for Structural heart disease. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 56.01B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 53.50B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 3.98B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 2.89B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY 1.05B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 3.58
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.54
- Shares Outstanding
- 1.11B
- Float Shares
- 440.27M
- Implied Shares Outstanding
- 1.11B
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
20.37%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
26.24%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
72.67%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
15.10%
- ROA Return on assets: net income ÷ total assets.
-
4.17%
- ROE Return on equity: net income ÷ shareholder equity.
-
7.08%
- Revenue Growth Year-over-year revenue growth.
-
-2.60%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 3.09
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.71
- Total Cash Cash and equivalents.
- CNY 2.71B
- Total Debt Short + long-term interest-bearing debt.
- CNY 153.16M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CNY -2.55B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.15
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY 1.13B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY 114.66M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
28.25%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
2.88%
- Cash Conversion (OpCF/EBITDA)
- 1.08
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.